Approfondimenti generali
Carcinoma della vescica, Linee Guida AIOM, 2015. [Apri]
Bellmunt J, et al.Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25, suppl. 3, iii40-iii48, 2014. [Apri]
Chen L. and Han X., Anti-PD-1/PD-L1 therapy of human cancer: Past, present and future. J Clin Invest 2015;125:3384–3391. [Apri]
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–247. [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Sidaway P. Urological cancer: Atezolizumab effective against advanced disease. Nat Rev Clin Oncol 2016; 13:266 [Apri]
Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558–62 [Apri]
Netto G. Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet 2016; 387:1881–1882 [Apri]
Bellmunt J, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol, 26: 812–17, 2015. [Apri]